Zavacorilant - Corcept Therapeutics
Alternative Names: CORT-125329Latest Information Update: 21 Jun 2024
Price :
$50 *
At a glance
- Originator Corcept Therapeutics
- Class
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurodegenerative disorders
- No development reported Weight gain
Most Recent Events
- 04 Jun 2024 Corcept Therapeutics completes a phase I trial in Neurodegenerative disorders (In volunteers) in United Kingdom (PO) (ISRCTN14072771)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Weight-gain(In volunteers) in United Kingdom (PO, Capsule)
- 27 Mar 2024 Phase-I clinical trials in Neurodegenerative disorders (In volunteers) in United Kingdom (PO) (ISRCTN14072771)